

## SUPPLEMENTARY MATERIALS

A total of 48 people were randomised and included in the study. Of these, 9 discontinued the trial, seven due to severe adverse effects and two due to personal issues. Dropouts were replaced leaving 19 people in the active group and 20 in the placebo group. Baseline differences between dropouts and remaining people in the liraglutide group are shown in Table S1. There were no significant differences between the groups, except that the dropouts had a significantly lower vibrations threshold ( $22\pm 11$  vs.  $18.5$  (18-22),  $p=0.012$ ).

**Table S1:**

**Baseline differences between dropouts and remaining participants in the liraglutide group**

	Dropouts (n=9)	Remaining (n=19)	P-value
Sex (male/%)	7/78%	17/89%	0.409
Age (years)	48±8	51±10	0.509
Disease duration (years)	30±12	32 ±11	0.688
HbA1c (mmol/mol) (NGSP units)	62±5 (7.8±2.6)	69±12 (8.5±3.2)	0.073
Vibration threshold (volts)	18.5 (18-22)	37±13	0.012
Smoking	2/22%	4/21%	0.944
Nausea/vomiting	0.00 (0.00-0.00)	0.00 (0.00-0.33)	0.629
Postprandial fullness	0.50 (0.25-0.75)	0.25 (0.00-0.75)	0.580
Bloating	0.00 (0.00-1.00)	0.00 (0.00-1.50)	1.000
GCSI	0.25 (0.08-0.53)	0.17 (0.08-1.00)	0.765

Data are means ± SD, medians (IQR) or N/%.

Vibration threshold is average of left and right and can only be measured up to 50